Hims & Hers Health Inc. (HIMS) saw its stock soar 5.22% in intraday trading on Thursday, outperforming the broader market. This surge was fueled by attention and buzz surrounding the telehealth company's provocative Super Bowl commercial criticizing weight-loss drug makers and the U.S. healthcare system.

While the controversial ad has prompted backlash from Senators Richard Durbin and Roger Marshall, who have requested an FDA investigation into potential misleading claims, it has also generated significant publicity for the company. Investors appear to be anticipating positive news from Hims & Hers' upcoming earnings report scheduled for February 24th, which could provide further insight into its performance and outlook.

Despite the controversy, Hims & Hers remains a highly rated stock in its industry group, with strong rankings for its Composite Rating, EPS Rating, and Relative Strength Rating. The stock's rally highlights the market's interest in the company and its ability to capitalize on the attention generated by its bold marketing strategy.